Related Experiment Video
Updated: Oct 9, 2025

A Murine Model of Hemodialysis Access-Related Hand Dysfunction
Published on: May 31, 2022
Evaluating Subjective and Objective Fatigue Immediately Before and After Hemodialysis: A Within-Subjects' Design
Bincy Joshwa1,2, Moh H Malek3, Rosalind M Peters4
1Assistant Professor, College of Nursing, Wayne State University, Detroit, MI.
Abstract:
Change in fatigue within a hemodialysis (HD) session has not been established previously. A total of 55 cognitively intact adults on HD were included; individuals with mobility/hemodynamic issues were excluded. Measures included the Piper Fatigue Scale-12 (PFS-12), 6-Minute Walk Test (6MWT), demographic and clinical. Descriptive statistics, ANOVA, and stepwise regression were used. Mean age was 57 years. Mean change in PFS-12 was -4.56 ± 27.85. Mean change in walk distance was -16.26 ± 43.87 meters (p = 0.03). The change in the PFS-12 accounted for 47% quadratic trend in the change in 6MWD (p < 0.001). Both fatigue measures (PFS-12 and 6MWT) can be useful for examining changes in fatigue levels within an HD session. Our findings speak to the convergent validity of these two measures of fatigue.
More Related Videos
04:36Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis
Published on: October 2, 2020
10:21Evaluation of Hydration Status by Bioelectrical Impedance Vector Analysis in Patients with Ischemic Heart Disease Undergoing Exercise Stress Test
Published on: September 22, 2023
Related Concept Videos
Hemodialysis III: Nursing Management
Hemodialysis II: Procedure and Complications
Hemodialysis I: Introduction
Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Bioavailability Study Design: Healthy Subjects Versus Patients
Heart Failure VI: Adjunct Therapies